News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
